In SCLC cells, FGFRL1 was found to interact with ENO1 (alpha-enolase), a protein involved in activation of the PI3K/AKT pathway in tumors, therefore FGFRL1 might modulate drug resistance in SCLC cells [242]. This evidence concerns the gene AKT1 and small cell lung carcinoma.